Industry News

FDA Approves Pegfilgrastim-cbqv

On March 6, 2023 the U.S Food and Drug Administration (FDA) approved a single-dose, prefilled autoinjector presentation of pegfilgrastim-cbqv, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. 

For more information read the Coherus Biosciences announcement

Posted 3/8/2023

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us